Biotech Values

[IanFromSI]

I suspect there's a better risk/reward opportunity for companies getting new chemical entities approved for large unmet medical needs than for companies seeking approval for a generic product.

Certainly, the former have more control over pricing.

To expect AGN to roll over and play dead is unlikely to be a successful investment strategy.

IMHO,
Ian